We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

82 hedge funds and large institutions have $83.6M invested in Palvella Therapeutics in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 27 increasing their positions, 21 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

29% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 21

22% more capital invested

Capital invested by funds: $68.8M → $83.6M (+$14.9M)

0.05% less ownership

Funds ownership: 0.79% → 0.75% (-0.05%)

7% less funds holding

Funds holding: 88 → 82 (-6)

38% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 16

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $56K

Holders
82
Holders Change
-6
Holders Change %
-6.82%
% of All Funds
1.45%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
10
Increased
27
Reduced
21
Closed
16
Calls
–
Puts
$56K
Net Calls
-$56K
Net Calls Change
-$73K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$1.84M
2
SFM
Sphera Funds Management
Israel
+$1.43M
3
JP Morgan Chase
JP Morgan Chase
New York
+$449K
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$397K
5
BlackRock
BlackRock
New York
+$176K

Top Sellers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
-$990K
2
Bank of America
Bank of America
North Carolina
-$609K
3
Russell Investments Group
Russell Investments Group
United Kingdom
-$479K
4
Cerity Partners
Cerity Partners
New York
-$468K
5
Renaissance Technologies
Renaissance Technologies
New York
-$311K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$13.7M – – –
ACM
2
Aquilo Capital Management
California
$9.19M – – –
BlackRock
3
BlackRock
New York
$9.08M +$176K +846 +2%
CS
4
Candriam SCA
Luxembourg
$5.68M -$91.3K -439 -2%
TCM
5
Tekla Capital Management
Massachusetts
$3.62M – – –
Renaissance Technologies
6
Renaissance Technologies
New York
$3.56M -$311K -1,496 -8%
WP
7
Woodline Partners
California
$2.88M -$990K -4,759 -25%
Citadel Advisors
8
Citadel Advisors
Florida
$2.82M -$64.7K -311 -2%
Vanguard Group
9
Vanguard Group
Pennsylvania
$2.8M +$97.7K +470 +3%
State Street
10
State Street
Massachusetts
$2.36M +$47.8K +230 +2%
Acadian Asset Management
11
Acadian Asset Management
Massachusetts
$2.19M -$169K -812 -7%
Morgan Stanley
12
Morgan Stanley
New York
$2.14M +$1.84M +8,834 +477%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$2.13M +$104K +499 +5%
OFM
14
Omega Fund Management
Massachusetts
$1.88M – – –
Assenagon Asset Management
15
Assenagon Asset Management
Luxembourg
$1.71M +$10.2K +49 +0.6%
Northern Trust
16
Northern Trust
Illinois
$1.45M +$46.4K +223 +3%
SFM
17
Sphera Funds Management
Israel
$1.38M +$1.43M +6,875 New
Jacobs Levy Equity Management
18
Jacobs Levy Equity Management
New Jersey
$1.34M +$397K +1,909 +40%
PIM
19
Platinum Investment Management
Australia
$1.27M – – –
SCM
20
Soleus Capital Management
Connecticut
$1.25M – – –
Citigroup
21
Citigroup
New York
$1.02M +$20.4K +98 +2%
Goldman Sachs
22
Goldman Sachs
New York
$778K -$67.4K -324 -8%
RPAM
23
Rhenman & Partners Asset Management
Sweden
$750K – – –
SPC
24
Sigma Planning Corp
Michigan
$580K +$28.3K +136 +5%
JP Morgan Chase
25
JP Morgan Chase
New York
$479K +$449K +2,161 +935%
1
2 3 4

PVLA Hedge Fund Activity: Q4 2020 in Review

82 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q4 2020, worth a combined $83.6M — up 22% from $68.8M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of PVLA and 10 opened new positions — a net loss of 6 holders — while 21 trimmed existing stakes and 27 added.

The largest buyer was Morgan Stanley, adding an estimated $1.84M. The largest seller was Woodline Partners, cutting an estimated $990K.

  • 82 institutional investors held Palvella Therapeutics (PVLA) as of Q4 2020, down from 88 in Q3 2020.
  • Funds reported $83.6M of Palvella Therapeutics stock for Q4 2020, up 22% quarter-over-quarter.
  • 10 funds opened new Palvella Therapeutics positions in Q4 2020 and 16 closed out, a net change of -6 holders.
  • The largest Palvella Therapeutics buyer in Q4 2020 was Morgan Stanley, an estimated $1.84M added.
  • The largest Palvella Therapeutics seller in Q4 2020 was Woodline Partners, an estimated $990K sold.

Based on aggregated 13F filings for Q4 2020.